PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
PHAR vs. TRMD
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PHAR and TRMD is 0.05, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.0

Performance

PHAR vs. TRMD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pharming Group NV (PHAR) and TORM plc (TRMD). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
17.19%
-45.38%
PHAR
TRMD

Key characteristics

Sharpe Ratio

PHAR:

-0.29

TRMD:

-0.96

Sortino Ratio

PHAR:

0.01

TRMD:

-1.31

Omega Ratio

PHAR:

1.00

TRMD:

0.85

Calmar Ratio

PHAR:

-0.33

TRMD:

-0.64

Martin Ratio

PHAR:

-0.74

TRMD:

-1.29

Ulcer Index

PHAR:

26.40%

TRMD:

25.35%

Daily Std Dev

PHAR:

67.26%

TRMD:

34.21%

Max Drawdown

PHAR:

-60.45%

TRMD:

-50.83%

Current Drawdown

PHAR:

-46.95%

TRMD:

-48.26%

Fundamentals

Market Cap

PHAR:

$612.12M

TRMD:

$2.32B

EPS

PHAR:

-$0.27

TRMD:

$8.08

Total Revenue (TTM)

PHAR:

$204.55M

TRMD:

$1.25B

Gross Profit (TTM)

PHAR:

$181.35M

TRMD:

$711.38M

EBITDA (TTM)

PHAR:

-$6.66M

TRMD:

$725.41M

Returns By Period

In the year-to-date period, PHAR achieves a -11.97% return, which is significantly lower than TRMD's -2.78% return.


PHAR

YTD

-11.97%

1M

-2.53%

6M

17.20%

1Y

-24.60%

5Y*

N/A

10Y*

N/A

TRMD

YTD

-2.78%

1M

-3.67%

6M

-45.39%

1Y

-32.55%

5Y*

34.49%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PHAR vs. TRMD — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PHAR
The Risk-Adjusted Performance Rank of PHAR is 3131
Overall Rank
The Sharpe Ratio Rank of PHAR is 3232
Sharpe Ratio Rank
The Sortino Ratio Rank of PHAR is 3333
Sortino Ratio Rank
The Omega Ratio Rank of PHAR is 3333
Omega Ratio Rank
The Calmar Ratio Rank of PHAR is 2727
Calmar Ratio Rank
The Martin Ratio Rank of PHAR is 3030
Martin Ratio Rank

TRMD
The Risk-Adjusted Performance Rank of TRMD is 88
Overall Rank
The Sharpe Ratio Rank of TRMD is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of TRMD is 66
Sortino Ratio Rank
The Omega Ratio Rank of TRMD is 99
Omega Ratio Rank
The Calmar Ratio Rank of TRMD is 1111
Calmar Ratio Rank
The Martin Ratio Rank of TRMD is 1212
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PHAR vs. TRMD - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Pharming Group NV (PHAR) and TORM plc (TRMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for PHAR, currently valued at -0.29, compared to the broader market-2.000.002.00-0.29-0.96
The chart of Sortino ratio for PHAR, currently valued at 0.01, compared to the broader market-4.00-2.000.002.004.006.000.01-1.31
The chart of Omega ratio for PHAR, currently valued at 1.00, compared to the broader market0.501.001.502.001.000.85
The chart of Calmar ratio for PHAR, currently valued at -0.33, compared to the broader market0.002.004.006.00-0.33-0.64
The chart of Martin ratio for PHAR, currently valued at -0.74, compared to the broader market-10.000.0010.0020.0030.00-0.74-1.29
PHAR
TRMD

The current PHAR Sharpe Ratio is -0.29, which is higher than the TRMD Sharpe Ratio of -0.96. The chart below compares the historical Sharpe Ratios of PHAR and TRMD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.00SeptemberOctoberNovemberDecember2025February
-0.29
-0.96
PHAR
TRMD

Dividends

PHAR vs. TRMD - Dividend Comparison

PHAR has not paid dividends to shareholders, while TRMD's dividend yield for the trailing twelve months is around 30.99%.


TTM20242023202220212020
PHAR
Pharming Group NV
0.00%0.00%0.00%0.00%0.00%0.00%
TRMD
TORM plc
30.99%30.13%23.05%6.99%0.00%14.89%

Drawdowns

PHAR vs. TRMD - Drawdown Comparison

The maximum PHAR drawdown since its inception was -60.45%, which is greater than TRMD's maximum drawdown of -50.83%. Use the drawdown chart below to compare losses from any high point for PHAR and TRMD. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-46.95%
-48.26%
PHAR
TRMD

Volatility

PHAR vs. TRMD - Volatility Comparison

Pharming Group NV (PHAR) has a higher volatility of 16.74% compared to TORM plc (TRMD) at 8.47%. This indicates that PHAR's price experiences larger fluctuations and is considered to be riskier than TRMD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
16.74%
8.47%
PHAR
TRMD

Financials

PHAR vs. TRMD - Financials Comparison

This section allows you to compare key financial metrics between Pharming Group NV and TORM plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab